Lisa A. Jackson, MD, MPH, is an internist and infectious disease epidemiologist who has conducted clinical and epidemiologic studies of vaccine safety and efficacy since 1991.
Dr. Jackson is the principal investigator (PI) of KPWHRI’s Vaccine and Treatment Evaluation Unit — one of 10 network sites that the National Institutes of Health (NIH) sponsors. In this role, she leads the phase 1 clinical trial of the COVID-19 vaccine co-developed by Moderna and NIH. Launched in March 2020, this trial was the first in the world to begin testing a COVID-19 vaccine. She is also leading the phase 3 clinical trials of the COVID-19 vaccines developed by Moderna and NIH and by Janssen Pharmaceutical Companies, part of Johnson & Johnson, at KPWHRI.
Additionally, Dr. Jackson serves as KPWHRI’s principal investigator in the Vaccine Safety Datalink Project (VSDP). Sponsored by the Centers for Disease Control and Prevention (CDC), VSDP conducts ongoing research on the safety of licensed vaccines in routine use.
Dr. Jackson has written more than 200 peer-reviewed publications and 14 book chapters. She is a past member of the Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee and the National Vaccine Program Office’s National Vaccine Advisory Committee.
After receiving her medical degree from the University of Virginia School of Medicine, in Charlottesville, Dr. Jackson earned her Master of Public Health (MPH) degree at the University of Washington (UW) School of Public Health. She completed her internal medicine residency training at the UW School of Medicine and served as an epidemic intelligence officer and preventive medicine resident at the CDC.
Vaccine safety; COVID-19 vaccine safety and effectiveness; influenza vaccine effectiveness in the elderly; methodologic issues in vaccine effectiveness evaluations; pneumococcal polysaccharide vaccine effectiveness; pneumococcal conjugate vaccine immunogenicity in the elderly; epidemiology of E. coli bacteremia; epidemiology of community-acquired pneumonia
Glanz JM, Clarke CL, Daley MF, Shoup JA, Hambidge SJ, Williams JTB, Groom HC, Kharbanda EO, Klein NP, Jackson LA, Lewin BJ, McClure DL, Xu S, DeStefano F. The childhood vaccination schedule and the lack of association with type 1 diabetes. Pediatrics. 2021 Dec 1;148(6):e2021051910. doi: 10.1542/peds.2021-051910. PubMed
El Sahly HM, Baden LR, Essink B, Doblecki-Lewis S, Martin JM, Anderson EJ, Campbell TB, Clark J, Jackson LA, Fichtenbaum CJ, Zervos M, Rankin B, Eder F, Feldman G, Kennelly C, Han-Conrad L, Levin M, Neuzil KM, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Polakowski L, Mascola JR, Ledgerwood JE, Graham BS, August A, Clouting H, Deng W, Han S, Leav B, Manzo D, Pajon R, Schödel F, Tomassini JE, Zhou H, Miller J; COVE Study Group. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. N Engl J Med. 2021 Sep 22. doi: 10.1056/NEJMoa2113017. Online ahead of print. PubMed
Kim SS, Chung JR, Belongia EA, McLean HQ, King JP, Nowalk MP, Zimmerman RK, Balasubramani GK, Martin ET, Monto AS, Lamerato LE, Gaglani M, Smith ME, Dunnigan KM, Jackson ML, Jackson LA, Tenforde MW, Verani JR, Kobayashi M, Schrag S, Patel MM, Flannery B. mRNA vaccine effectiveness against COVID-19 among symptomatic outpatients aged =16 years in the United States, February - May 2021. J Infect Dis. 2021 Sep 8:jiab451. doi: 10.1093/infdis/jiab451. Online ahead of print. PubMed
Pegu A, O'Connell S, Schmidt SD, O'Dell S, Talana CA, Lai L, Albert J, Anderson E, Bennett H, Corbett KS, Flach B, Jackson L, Leav B, Ledgerwood JE, Luke CJ, Makowski M, Nason MC, Roberts PC, Roederer M, Rebolledo PA, Rostad CA, Rouphael NG, Shi W, Wang L, Widge AT, Yang ES; mRNA-1273 Study Group, Beigel JH, Graham BS, Mascola JR, Suthar MS, McDermott AB, Doria-Rose NA. Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. Science. 2021 Aug 12:eabj4176. doi: 10.1126/science.abj4176. [Epub ahead of print]. PubMed
Griggs EP, Flannery B, Foppa IM, Gaglani M, Murthy K, Jackson ML, Jackson LA, Belongia EA, McLean HQ, Martin ET, Monto AS, Zimmerman RK, Balasubramani GK, Chung JR, Patel M, Us Flu Ve Investigators OBOT. Role of Age in Spread of Influenza, 2011-2019, U.S. Influenza Vaccine Effectiveness Network. LID - kwab205 [pii] LID - 10.1093/aje/kwab205 [doi] Am J Epidemiol. 2021 Jul 16:kwab205. doi: 10.1093/aje/kwab205 [Epub ahead of print] PubMed
Razzaghi H, Meghani M, Pingali C, Crane B, Naleway A, Weintraub E, Kenigsberg TA, Lamias MJ, Irving SA, Kauffman TL, Vesco KK, Daley MF, DeSilva M, Donahue J, Getahun D, Glenn S, Hambidge SJ, Jackson L, Lipkind HS, Nelson JC, Zerbo O, Oduyebo T, Singleton JA, Patel SA. COVID-19 vaccination coverage among pregnant women during pregnancy - eight integrated health care organizations, United States, December 14, 2020-May 8, 202. MMWR Morb Mortal Wkly Rep. 2021 Jun 18;70(24):895-899. doi: 10.15585/mmwr.mm7024e2. PubMed
Naleway AL, Crane B, Irving SA, Bachman D, Vesco KK, Daley MF, Getahun D, Glenn SC, Hambidge SJ, Jackson LA, Klein NP, McCarthy NL, McClure DL, Panagiotakopoulos L, Panozzo CA, Vazquez-Benitez G, Weintraub ES, Zerbo O, Kharbanda EO. Vaccine Safety Datalink infrastructure enhancements for evaluating the safety of maternal vaccination. Ther Adv Drug Saf. 2021 Jun 14;12:20420986211021233. doi: 10.1177/20420986211021233. eCollection 2021. PubMed
Liles E, Irving SA, Dandamudi P, Belongia EA, Daley MF, DeStefano F, Jackson LA, Jacobsen SJ, Kharbanda E, Klein NP, Weintraub E, Naleway AL. Incidence of pediatric inflammatory bowel disease within the Vaccine Safety Datalink network and evaluation of association with rotavirus vaccination. Vaccine. 2021;39(27):3614-3620. doi: 10.1016/j.vaccine.2021.05.032. Epub 2021 May 26. PubMed
Chung JR, Flannery B, Kim SS, Gaglani M, Raiyani C, Belongia EA, McLean HQ, Nowalk MP, Zimmerman RK, Jackson ML, Jackson LA, Martin ET, Monto AS, Patel M. Sample size considerations for mid-season estimates from a large influenza vaccine effectiveness network in the United States. Vaccine. 2021 May 13:S0264-410X(21)00555-7. doi: 10.1016/j.vaccine.2021.05.004. Online ahead of print. PubMed
Murphy SC, Deye GA, Sim BKL, Galbiati S, Kennedy JK, Cohen KW, Chakravarty S, Kc N, Abebe Y, James ER, Kublin JG, Hoffman SL, Richie TL, Jackson LA. PfSPZ-CVac efficacy against malaria increases from 0% to 75% when administered in the absence of erythrocyte stage parasitemia: A randomized, placebo-controlled trial with controlled human malaria infection. PLoS Pathog. 2021 28;17(5):e1009594. doi: 10.1371/journal.ppat.1009594. eCollection 2021 May. PubMed
KPWHRI to access the benefits of mixing different vaccine types in NIAID-sponsored study.
Dr. Rita Mangione-Smith reflects on the year since KPWHRI launched the world's first clinical trial for a COVID-19 vaccine.
Lisa Jackson, MD, MPH, Kaiser Permanente Washington senior investigator, recounts the genesis of a groundbreaking vaccine.
Seattle NPR affiliate KUOW-FM, April 8, 2021
On March 16, 2020, Jennifer Haller became the first person to be injected with a COVID-19 vaccine in a clinical trial.
People, March 4, 2021